Non-alcoholic Fatty Liver Disease (nafld) Market Size & Share Analysis - Growth, Trends, And Forecasts (2024 - 2029)

The Non-Alcoholic Fatty Liver Disease (NAFLD) Market Report is Segmented by Drug Class (Antioxidants, Lipid-Lowering Agents, Thiazolidinedione, FXR Receptor Agonists, Fibrosis Treatment Agents, Biguanides, and Other Drug Classes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Market Size and Forecast for all the Above Segments in Value (USD).

Non-alcoholic Fatty Liver Disease (nafld) Market Size & Share Analysis - Growth, Trends, And Forecasts (2024 - 2029)

Non-Alcoholic Fatty Liver Disease (NAFLD) Industry Overview

The non-alcoholic fatty liver disease market is consolidated in terms of ongoing research and development and pharmaceutical pipeline development. The pharmaceutical landscape for NAFLD is dominated by companies that are heavily investing in developing therapeutics for the condition. Some of the key players are Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Gilead Sciences Inc., AbbVie Inc., and Novo Nordisk AS.

Non-Alcoholic Fatty Liver Disease (NAFLD) Market Leaders

  1. Intercept Pharmaceuticals

  2. Madrigal Pharmaceuticals

  3. Novo Nordisk A/S

  4. Gilead Sciences, Inc.

  5. AbbVie, Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Non-Alcoholic Fatty Liver Disease (NAFLD) Market Concentration

Non-Alcoholic Fatty Liver Disease (NAFLD) Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?